Your browser doesn't support javascript.
loading
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton, Stéphane; Montesinos, Pau; Schuh, Andre C; Papayannidis, Cristina; Vyas, Paresh; Wei, Andrew H; Ommen, Hans; Semochkin, Sergey; Kim, Hee-Je; Larson, Richard A; Koprivnikar, Jaime; Frankfurt, Olga; Thol, Felicitas; Chromik, Jörg; Byrne, Jenny; Pigneux, Arnaud; Thomas, Xavier; Salamero, Olga; Vidriales, Maria Belen; Doronin, Vadim; Döhner, Hartmut; Fathi, Amir T; Laille, Eric; Yu, Xin; Hasan, Maroof; Martin-Regueira, Patricia; DiNardo, Courtney D.
Affiliation
  • de Botton S; Gustave Roussy, Université Paris-Saclay, Villejeuf, France.
  • Montesinos P; Hospital Universitari i Politecnic La Fe, Valencia, Spain.
  • Schuh AC; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Vyas P; Oxford Biomedical Research Centre and Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.
  • Wei AH; The Alfred Hospital, Melbourne, VIC, Australia.
  • Ommen H; Monash University, Melbourne, VIC, Australia.
  • Semochkin S; Aarhus University Hospital, Århus, Denmark.
  • Kim HJ; Pirogov Russian National Research Medical University, Moscow, Russian Federation.
  • Larson RA; Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Koprivnikar J; University of Chicago Comprehensive Cancer Center, Chicago, IL.
  • Frankfurt O; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.
  • Thol F; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
  • Chromik J; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hanover, Germany.
  • Byrne J; Universitätsklinikum Frankfurt, Frankfurt, Germany.
  • Pigneux A; Nottingham University Hospitals Trust, Nottingham, United Kingdom.
  • Thomas X; Bordeaux Haut-Leveque University Hospital, Pessac, France.
  • Salamero O; Centre Hospitalier Universitaire de Lyon-Sud, Lyon, France.
  • Vidriales MB; Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Doronin V; University Hospital of Salamanca and Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
  • Döhner H; City Clinical Hospital No. 40, Moscow, Russian Federation.
  • Fathi AT; Universitätsklinikum Ulm, Ulm, Germany.
  • Laille E; Massachusetts General Hospital Cancer Center, Boston, MA.
  • Yu X; Harvard Medical School, Boston, MA.
  • Hasan M; Bristol Myers Squibb, Princeton, NJ.
  • Martin-Regueira P; Bristol Myers Squibb, Princeton, NJ.
  • DiNardo CD; Bristol Myers Squibb, Princeton, NJ.
Blood ; 141(2): 156-167, 2023 01 12.
Article in En | MEDLINE | ID: mdl-35714312
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Isocitrate Dehydrogenase Type of study: Clinical_trials Limits: Aged / Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Isocitrate Dehydrogenase Type of study: Clinical_trials Limits: Aged / Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: France